Effects of Dexmedetomidine Pretreatment Under TIVA on Expression of Inflammatory Factors and Immune Function in radical resection of colon cancer

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2000028789

Enrollment

Unknown

Registered

2020-01-04

Start date

2020-01-01

Completion date

Unknown

Last updated

2020-01-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Colon cancer

Interventions

Experimental group:Give dexmedetomidine 1ug / kg pump 15 minutes before induction of anesthesia

Control group:Pump in same volume N.S.

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. 100 Patients undergoing laparoscopic radical colonectomy from 2020.1 to 2021.1; 2. ASA I to III grade; 3. Aged 18 to 65 years.

Exclusion criteria

Exclusion criteria: 1. Patients with severe infections or respiratory diseases; 2. Patients with severe arrhythmia or bradycardia; 3. Patients with severe diseases of liver, kidney, endocrine or immune system; 4. Patients who are given an alpha-adrenergic agonist or a beta-receptor antagonist; 5. Patients with fever before surgery; 6. Patients receiving chemotherapy, radiotherapy or immunotherapy within 1 month before surgery; 7. Patients have a habit of smoking or drinking too much alcohol.

Design outcomes

Primary

Measure	Time frame
IL-1beta;IL-6;TNF-alpha;NF-kB;CD3+;CD4+;CD8+;	—

Secondary

Measure	Time frame
Hemodynamics;SAS;Total opioid use;visual analogue scale;time during the PACU;Adverse reactions;	—

Countries

China

Contacts

Public ContactBin Gao

Huzhou Central Hospital

gaobin1002@126.com+86 18705828802

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026